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21-hydroxylase-deficient congenital adrenal hyperplasia (CAH), an autosomal recessive condition, is associated with varying extent of impaired cortisol and aldosterone synthesis and adrenal androgen excess. 1 Increase in ACTH secretion due to cortisol deficiency causes bilateral adrenal gland hyperplasia and raised earlier cortisol precursors below the mutant block. 1 The dosage of glucocorticoids and mineralocorticoids for preventing adrenal crises should be carefully adjusted to avoid the effects of either over-treatment with glucocorticoids or overproduction adrenal androgens. 2, 3 A large number of electrocardiogram (ECG) derived indexes have been described for assessing the tendency for atrial and ventricular rhythm disturbances in various clinical conditions. Previously, the predictive value of P-wave dispersion (PWd), QT and corrected QT (QTc) intervals, QT and QTc dispersions for atrial, ventricular arrhythmias and sudden cardiac death (SCD) has been well described. [4] [5] [6] [7] [8] [9] [10] [11] In recent years, T-wave peak-to-end (Tp-e) interval, which is the interval between the peak and the end of the T-wave on ECG, has emerged as a marker of the transmural dispersion of repolarization (TDR). Additionally, the Tp-e/QT and Tp-e/QTc ratios are used as an index for susceptibility to ventricular arrhythmogenesis.
Lifelong glucocorticoid treatment in patients with 21 hydroxylase deficiency may result in increased cardiovascular risk factors such as, obesity, insulin resistance with type 2 diabetes (T2DM), and hypertension. The early stage of hypertension was associated with an increased risk of myocardial fibrosis, ventricular hypertrophy and arrhythmias 12 . Glucocorticoids given in supraphysiological dose, play a role in myocardial fibrosis and cardiac hypertrophy with mineralocorticoid receptor (MR) activation. [13] [14] Myocardial fibrosis and remodeling may result in ventricular arrhythmias. To date, no study has been conducted to assess the impact of the disease and hydrocortisone treatment on electrocardiographic measures in children with 21-hydroxylase-deficient CAH. The purpose of this study is to assess the 12-lead electrocardiographic measures such as PWd, QT interval, QTd, Tp-e interval, Tp-e/QT and Tp-e/QTc ratio in patients with 21-hydroxylasedeficient CAH.
Material and Methods

Patient population
Twenty-five patients with 21-hydroxylasedeficient CAH and twenty-five age, sex and body size matched healthy control subjects were enrolled into this observational, crosssectional, controlled study. The children with 21-hydroxylase-deficient CAH were recruited consecutively from the outpatient clinic of the Pediatric Endocrinology, Dr. Behçet Uz Children's Hospital. 21-hydroxylase-deficient children who were recruited in this study were regularly followed at our institution from diagnosis, had adequate clinical and hormonal control, with a disease duration >12 months, and had no chronic diseases other than 21-hydroxylase-deficient CAH. Measurements included height and weight. The wall-mounted "Harpenden" stadiometer, which is similar to that designed by Tanner and Whitehouse, was used to measure height. Body mass index (BMI) was calculated (kg/m 2 ). The standards of Greulich-Pyle method were used to assess bone age from radiographs of the left hand. At the time of diagnosis, all patients showed high basal levels of 17-hydroxyprogesterone (17-OHP) (>50 µg/L). The diagnosis of 21-hydroxylasedeficiency was confirmed by identification of homozygous or compound heterozygous CYP21A2 mutations. The patients were treated with hydrocortisone divided into three doses. The patients with salt wasting also received 9-α-fludrocortisone 0.1 mg/day. None of the patients received additional medication.
The control group comprised children with no chronic illness. Written informed consent was acquired from the legal guardians of the children. The study was conducted according to the Declaration of Helsinki and the study protocol had been approved by Ethics Committee for Dr. Behcet Uz Children Hospital. The number of the document which verified approval of the study was 2014/06-02 (10.04.2014).
Blood pressure measurements
Blood pressure (BP) measurement was performed with using a conventional oscillatory measurement system positioned at the rightupper arm (DINAMAP; GE Healthcare, Munchen, Germany). The size of the cuff was selected for the patient's arm circumference, with the cuff bladder covering at least 40% and a maximum of 100% of the arm circumference. Standard deviation scores were obtained from normative values according to the literature. 15 
Laboratory methods
Blood samples were taken at 8:00 a.m. before the first dose of steroids and after an overnight fasting at least 12 hours. Fasting glucose, triglycerides, total cholesterol, and high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol were measured by standard laboratory methods. Each sample was processed immediately after a maximum delay of 1 hour.
Adrenocorticotropic hormone (ACTH), plasma 17-OHP, serum cortisol, androstenedione and dehydroepiandrosterone sulphate (DHEA-S) were also measured. Serum insulin, androstenedione, ACTH and 17-OHP measurements were performed with commercially available RIA kits (Siemens Healthcare Diagnostics, Inc., LA, CA, USA).
We calculated the homeostasis model assessment of insulin resistance (HOMA-IR) by using the formula: fasting insulin (µU/ml) 
Electrocardiography
The standard 12-lead ECG (Cardiofax GEM, Model 9022 K; Nihon Kohden, Tokyo, Japan) was recorded at a speed of 25 mm/sec and an amplitude of 1 mV/cm while in the supine position. ECG recordings were transferred to a personal computer. After 400x zooming in Adobe Photoshop software, measurements were performed directly from these ECG tracings by two pediatric cardiologists who were blinded to the patients files.
P-wave dispersion
P-wave duration was measured as the time between the beginning of the P-wave and the ending point of the P-wave. PWd was measured from the difference between the maximum and minimum P-wave durations. 4
QT dispersion
The QT interval was measured from the onset of the QRS complex to the end of the T-wave.
If T-waves had two peaks and the second was smaller than 50% of the first one, then the point where the first peak reached the isoelectric line was considered the end of the T-wave. The corrected QT (QTc) interval was measured according to Bazzet's formula. 17 The dispersion of the QT interval was obtained from the difference between the maximum and minimum QT interval.
Tp-e interval
The Tp-e interval was measured as duration from the peak of the T-wave and the end of the T-wave. If a lead contained inverted T-waves, we got the measurement from the lowest point of the inverted T-wave to its end. The U-wave was not taken into consideration. 18 The dispersion of the Tp-e interval was measured as the differences between the maximum and the minimum Tp-e interval. The Tp-e/QT and Tp-e/QTc ratios were calculated from these measurements. 19
Follow-Up Protocol
In We carried out independent-samples t-test and Mann-Whitney U-tests to compare the two independent groups. Pearson and Spearman correlation tests were also employed to assess the strength of association between two variables. The quantitative data were expressed as median (minimum-maximum). The data were analysed at a 95% confidence level and considered significant at a P value of <0.05.
Results
The median age of patients was 9.4 years (1.5-16.75), and the mean weight was 35.5 (7.5-76.3) kg. The median duration of treatment was 52.2 months (12-186 months). Patients' bone age, laboratory characteristics, mean hydrocortisone and fludrocortisone dosages are shown in Table I . Fifteen patients were receiving both hydroxycortisone and fludrocortisone, while 10 were on hydroxycortisone only. The median hydrocortisone dose was 18.8 (9.2-23.9) mg/m 2 /day. There was no significant correlation between hydrocortisone dose and systolic (P: 0.12) and diastolic (0.46) blood pressures. Also, the median systolic blood pressure and diastolic blood pressure in patients receiving 9-a-fludrocortisone were not different from those in patients on hydrocortisone only (P: 0.2). The CYP21A2 mutations included p.Q318X in seven patients, p.I172N in six, p.I2A in five, p.V28IL in three, p.R356W in two and 8-bp-deletion in two.
The patient group did not differ from the healthy group in terms of age, body mass index, diastolic blood pressure or plasma levels of triglyceride, cholesterol, LDL and HDL. However, systolic blood pressure was significantly higher in the patient group compared to healthy subjects (Table II) (Table III) . Diastolic blood pressure was significantly positively correlated with weight (p<0.001, r: 0.69), height (p<0.001, r: 0.67), BMI (p: 0.005, r: 0.54), bone age (p: 0.01, r: 0.46), treatment duration (p: 0.005, r: 0.54) (Table III) . (Table  IV) . P dispersion was positively correlated with systolic blood pressure (p: 0.01, r: 0.489) and treatment duration (r: 0.397, p: 0.05). T peakend dispersion was positively correlated with systolic blood pressure (p: 0.004, r: 0.559), BMI (p: 0.004, r: 0.551) and treatment duration (p: 0.02, r: 0.455). According to the clinical and laboratory measures described above, eight patients were deemed to be uncontrolled. (Table IV) .
Discussion
Researchers have found that 21-hydroxylase d e f i c i e n t C A H i s a r i s k f a c t o r f o r hypertension, obesity, dyslipidemia, and insulin resistance. 3, [21] [22] [23] [24] Our previous study found disturbance of ventricular functions in patients with CAH, using tissue Doppler imaging techniques in these patients. 25 However, data are still lacking regarding the effects of CAH on electrocardiographic measures in children with 21-hydroxylase-deficient CAH. In this study we found that 21-hydroxylase deficient CAH is associated with some adverse effects on electrocardiographic parameters among children and adolescents. To our knowledge, this study is the first to assess the increased risk for atrial and ventricular arrhythmias in children with 21-hydroxylase-deficient CAH using standard 12-lead electrocardiography.
In this study, we found a significant positive correlation between T peak-end dispersion and systolic blood pressure. We also found a significant positive correlation of T peak-end dispersion with hydroxycortisone treatment duration and BMI. These effects may be due to activated glucocorticoid and mineralocorticoid receptors on arterial and heart tissue, increased contractility of vascular tissue by enhancing sensitivity to noradrenaline and reduced endothelium dependent vasodilation. 26 Ventricular cardiac arrhythmias have been considered as one of the first electrocardiographic abnormalities to appear in early hypertensive rats 12 . Increased risk of high systolic blood pressure has been attributed to weight, BMI, duration of hydroxycortisone treatment, dyslipidemia, and insulin resistance. We found a significant correlation of high systolic blood pressure with hydroxycortisone treatment duration, dyslipidemia and insulin resistance in our study. Cortisol deficiency induces an increase in ACTH levels and results in high 17 hydroxy progesterone levels and adrenal androgen excess in uncontrolled patients with CAH. High dose glucocorticoid replacement is required for suppressing high ACTH levels in uncontrolled patients, which contributes to high systolic blood pressure leading to ventricular hypertrophy inducing ventricular cardiac arrhythmias and death. A recent study demonstrated that children with CAH had left ventricular hypertrophy and impaired left ventricular diastolic dysfunction. 20 We also found that patients with uncontrolled CAH had susceptibility for atrial and ventricular arrhythmias because of high dose glucocorticoid requirement, which suggested an association between CAH and risk of ventricular arrhythmias and death.
In this study, we found significant positive correlations between the duration of hydroxycortisone treatment and P dispersion, which indicated a predisposition to atrial arrhythmias. Previous studies regarding the relationship between corticosteroids and the risk of atrial fibrillation have been reported. 27, 28 Hydroxycortisone can have mineralocorticoid receptor (MR) associated with atrial fibrillation. 27 Laszlo et al. 29 demonstrated that MR antagonism stabilizes atrial electrophysiology by altering atrial ionic channels. Another mechanism of atrial fibrillation due to corticosteroids was a transient increase in serum potassium. 30 Tp-e dispersion, which represents repolarization and modifications in normal pattern of ventricular recovery, has demonstrated to be effective to predict malignant arrhythmias in medical conditions. 31, 32 It has been proposed to be more useful than QTc and its dispersion in some clinical conditions. 33 A recent study showed patients with uncontrolled CAH on medical treatment had more severe left ventricular hypertrophy and heart endothelial injury. 20 We also found detrimental effects on ventricular functions in these uncontrolled patients. We reported increased susceptibility of 21-hydroxylase deficiency to ventricular cardiac arrhythmias and death in uncontrolled children and adolescents. Nguyen et al. 12 found that interstitial myocardial fibrosis due to early hypertension was associated with adverse structural and electrical remodeling changes. Nguyen et al. 12 hypothesized that basic differences in intracellular calcium cycling dynamics caused early after depolarization in ventricular myocytes from spontaneously hypertensive rats. Tp-e dispersion affected by levels of systolic blood pressure was significantly higher in the patient group and positively correlated with systolic blood pressure. CAH might exert its detrimental effects on ventricular arrhythmias by increasing blood pressure levels.
Our study had several limitations primarily being that it was an observational singleinstitution study that had a relatively small sample size. An additional limitation of our study might be a potential bias caused by inconsistent measurements of serum 1 7 -h y d r o x y p r o g e s t e r o n e , D H E A-S O 4 , Androstenedione and ACTH, because only data from patients in only one center with CAH were included in this study. Another limitation of our study is wide range of patients' age. Absence of 24-hour Holter monitoring and cardiac stress testing for the assessment of atrial and ventricular arrhythmias further limited the study. Performing 24-hour Holter monitoring and cardiac stress testing in patients with 21-hydroxylase deficient CAH would be interesting.
Nevertheless, this is the first study to show an association between atrial and ventricular arrhythmias and 21-hydroxylase deficient CAH. Our results demonstrated that children and adolescents with 21-hydroxylase-deficient CAH are more prone to some electrocardiographic changes which may lead to atrial and ventricular arrhythmias. Thus, these patients should be carefully evaluated with 12-lead ECG in terms of this electrocardiographic changes even in the absence of atrial and ventricular arrhythmias. Further prospective studies with large number of patients are needed to show prognostic value of these ECG parameters.
